BACKGROUND: Neuroblastoma is a heterogeneous pediatric disease. Most patients with localized disease usually have a favorable prognosis, but patients with advanced disease have a poor prognosis despite combination chemotherapy. Treatment failure may be attributable to resistance to cytotoxic drugs. PROCEDURE: Using quantitative RT-PCR, we investigated the clinical significance of the level of mRNA expression of multidrug resistance genes (MDR1, MRP1, MRP5, LRP) in a series of 29 advanced neuroblastoma samples. RESULTS: At the end of induction chemotherapy, 48% of patients achieved a clinical complete response, 28% achieved a partial response or stable disease, and 24% presented progressive disease. MDR1 mRNA overexpression (i.e., mRNA level >2 copies of MDR1 gene) was observed in 74% of samples, and MRP1, MRP5, LRP overexpression was observed less frequently (30, 33, and 33% of samples, respectively). None of these parameters were predictive of response, relapse, or survival. However, clinical response to treatment was highly predictive of relapse-free survival and overall survival. CONCLUSIONS: High expression of these multidrug resistance genes in advanced neuroblastoma is not the main parameter of response to cytotoxic drugs; clinical response to treatment remains the most important parameter in predicting the prognosis of patients with advanced neuroblastoma, until other relevant laboratory parameters have been identified. (c) 2006 Wiley-Liss, Inc.
BACKGROUND:Neuroblastoma is a heterogeneous pediatric disease. Most patients with localized disease usually have a favorable prognosis, but patients with advanced disease have a poor prognosis despite combination chemotherapy. Treatment failure may be attributable to resistance to cytotoxic drugs. PROCEDURE: Using quantitative RT-PCR, we investigated the clinical significance of the level of mRNA expression of multidrug resistance genes (MDR1, MRP1, MRP5, LRP) in a series of 29 advanced neuroblastoma samples. RESULTS: At the end of induction chemotherapy, 48% of patients achieved a clinical complete response, 28% achieved a partial response or stable disease, and 24% presented progressive disease. MDR1 mRNA overexpression (i.e., mRNA level >2 copies of MDR1 gene) was observed in 74% of samples, and MRP1, MRP5, LRP overexpression was observed less frequently (30, 33, and 33% of samples, respectively). None of these parameters were predictive of response, relapse, or survival. However, clinical response to treatment was highly predictive of relapse-free survival and overall survival. CONCLUSIONS: High expression of these multidrug resistance genes in advanced neuroblastoma is not the main parameter of response to cytotoxic drugs; clinical response to treatment remains the most important parameter in predicting the prognosis of patients with advanced neuroblastoma, until other relevant laboratory parameters have been identified. (c) 2006 Wiley-Liss, Inc.
Authors: Unmesh Jadhav; Ravesanker Ezhilarasan; Steven F Vaughn; Mark A Berhow; Sanjeeva Mohanam Journal: Int J Mol Med Date: 2007-03 Impact factor: 4.101
Authors: Aghiad Chamdin; Jason A Jarzembowski; Chitra Subramanian; Rork Kuick; Julia Shin-Jung Lee; Roland Ps Kwok; Valerie P Castle; Anthony W Opipari Journal: Transl Oncol Date: 2009-08-18 Impact factor: 4.243
Authors: Marc A Bollet; Alexia Savignoni; Leanne De Koning; Carine Tran-Perennou; Catherine Barbaroux; Armelle Degeorges; Brigitte Sigal-Zafrani; Geneviève Almouzni; Paul Cottu; Rémy Salmon; Nicolas Servant; Alain Fourquet; Patricia de Cremoux Journal: Breast Cancer Res Date: 2009-07-28 Impact factor: 6.466
Authors: L de Plater; A Laugé; C Guyader; M-F Poupon; F Assayag; P de Cremoux; A Vincent-Salomon; D Stoppa-Lyonnet; B Sigal-Zafrani; J-J Fontaine; R Brough; C J Lord; A Ashworth; P Cottu; D Decaudin; E Marangoni Journal: Br J Cancer Date: 2010-09-28 Impact factor: 7.640